Discussion This study shows that administration of metformin 30 and 60 min before an intraduodenal glucose load is more effective than its administration at the start of the glucose infusion in terms of both reducing glycaemia and augmenting GLP-1 release in participants with metformin-treated type 2 diabetes
Novo Nordisk also took legal action against Hims & Hers, alleging that the telehealth provider was unlawfully mass marketing unapproved versions of Novo Nordisks FDA-approved semaglutide medicines (Wegovy and Ozempic)
That "side effect" clinicians have managed for 30 years
In recent years, the therapeutic footprint of this class has grown: long-acting agents (e.g., liraglutide, semaglutide) and next-generation dual/triple agonists (e.g., tirzepatide) have demonstrated superior glycemic control, weight reduction, and cardiovascular benefits in adults with T2DM (Yao et al., 2024)
Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome
Diabetes 53(9):24922500 Balkan B, Li X (2000) Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms